

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Brilliant Violet 750(TM) anti-mouse CD3

RRID:AB_2734148

Type: Antibody

Proper Citation

BioLegend Cat# 100249, RRID:AB_2734148

Antibody Information

URL: http://antibodyregistry.org/AB_2734148

Proper Citation: BioLegend Cat# 100249, RRID:AB_2734148

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 750(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2734148

Vendor: BioLegend

Catalog Number: 100249

Record Creation Time: 20250820T060048+0000

Record Last Update: 20250820T230428+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 750(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 750(TM) anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Verwaerde S, et al. (2026) Innate type 2 lymphocytes trigger an inflammatory switch in alveolar macrophages. *Immunity*, 59(1), 60.

Fischer TD, et al. (2026) Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic ?PD-1 Activate Tumor-Specific CD8+ T Cells. *Cancer research communications*, 6(5), 1006.

Boutet M, et al. (2025) Mutations in MLL3 promote breast cancer progression via HIF1?-dependent intratumoral recruitment and differentiation of regulatory T cells. *Immunity*, 58(8), 2035.

Janas PP, et al. (2025) Epithelial Memory After Respiratory Viral Infection in Mice Results in Prolonged Enhancement of Antigen Presentation. *Allergy*, 80(9), 2501.

Revach OY, et al. (2025) Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants. *Cell reports. Medicine*, 6(7), 102210.

Sprooten J, et al. (2024) Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells. *Cell reports. Medicine*, 5(1), 101377.

Bugno J, et al. (2024) Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(19), 4450.

Liu Y, et al. (2023) A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression. *Developmental cell*, 58(23), 2700.

Christian DA, et al. (2022) cDC1 coordinate innate and adaptive responses in the omentum required for T cell priming and memory. *Science immunology*, 7(75), eabq7432.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. *Cell reports*, 41(3), 111478.

Pelgrom LR, et al. (2022) mTORC1 signaling in antigen-presenting cells of the skin restrains CD8+ T cell priming. *Cell reports*, 40(1), 111032.